• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Tertiary alcohols
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alcohols and polyols Tertiary alcohols

Professional Introduction to 3-Cyclopropylazetidin-3-ol Hydrochloride (CAS No. 848192-93-8)

3-Cyclopropylazetidin-3-ol hydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 848192-93-8, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This zwitterionic derivative has garnered attention due to its structural uniqueness and potential biological activities, making it a subject of extensive investigation in drug discovery and development.

The molecular framework of 3-cyclopropylazetidin-3-ol hydrochloride features a cyclopropyl substituent attached to an azetidine ring, which is further functionalized with a hydroxyl group at the 3-position. This specific arrangement imparts distinct steric and electronic properties, influencing its interactions with biological targets. The hydrochloride salt form enhances its solubility in aqueous media, facilitating its use in various biochemical assays and pharmacological studies.

In recent years, there has been growing interest in azetidine derivatives as scaffolds for developing novel therapeutic agents. The cyclopropyl moiety, in particular, has been shown to modulate the binding affinity and selectivity of small molecules toward enzymes and receptors. Studies have demonstrated that such structural motifs can improve pharmacokinetic profiles by enhancing metabolic stability and reducing off-target effects.

One of the most compelling aspects of 3-cyclopropylazetidin-3-ol hydrochloride is its potential as an intermediate in the synthesis of more complex pharmacophores. Researchers have leveraged this compound to explore its reactivity in cross-coupling reactions, allowing for the introduction of diverse functional groups while maintaining the core azetidine scaffold. This flexibility has enabled the creation of libraries of derivatives with tailored biological activities.

Recent advancements in computational chemistry have further illuminated the therapeutic potential of 3-cyclopropylazetidin-3-ol hydrochloride. Molecular docking simulations have identified its binding interactions with various protein targets, including kinases and transcription factors implicated in inflammatory and oncogenic pathways. These findings suggest that this compound may serve as a lead molecule for developing inhibitors with therapeutic relevance.

The synthesis of 3-cyclopropylazetidin-3-ol hydrochloride involves multi-step organic transformations, starting from readily available precursors. The introduction of the cyclopropyl group is typically achieved through ring-closing metathesis or cyclopropanation reactions, while the azetidine ring is constructed via intramolecular cyclization strategies. The final step involves salt formation with hydrochloric acid to enhance stability and handling properties.

Evaluation of 3-cyclopropylazetidin-3-ol hydrochloride in preclinical models has revealed promising results in terms of bioactivity and safety profiles. In vitro assays have shown inhibitory effects on several key enzymes, warranting further investigation into its mechanism of action. Additionally, preliminary toxicology studies indicate moderate solubility and low acute toxicity, suggesting a favorable safety profile for future clinical development.

The pharmaceutical industry continues to explore novel analogs of 3-cyclopropylazetidin-3-ol hydrochloride to optimize their pharmacological properties. By modifying substituents on the azetidine ring or introducing additional functional groups, researchers aim to enhance potency, selectivity, and oral bioavailability. These efforts are supported by high-throughput screening technologies that accelerate the identification of promising candidates for further development.

The role of 3-cyclopropylazetidin-3-ol hydrochloride as a building block in medicinal chemistry underscores its importance in drug discovery initiatives. Its unique structural features offer opportunities for designing molecules with improved pharmacological profiles compared to existing therapies. As research progresses, this compound is expected to contribute significantly to the development of new treatments for various diseases.

In conclusion, 3-cyclopropylazetidin-3-ol hydrochloride (CAS No. 848192-93-8) represents a valuable asset in pharmaceutical research due to its structural complexity and potential biological activities. Its synthesis, characterization, and preclinical evaluation continue to advance our understanding of azetidine derivatives as therapeutic agents. With ongoing investigations into its pharmacology and chemical modifications, this compound holds promise for future medical applications.

• 1523292-46-7(3-(Pentan-3-yl)azetidin-3-ol)
• 1593791-94-6(3-(cyclopropylmethyl)azetidin-3-ol)
• 1394042-85-3(3-Azabicyclo[4.1.0]heptan-1-ol hydrochloride)
• 2387600-80-6(3-(cyclopropylmethyl)azetidin-3-ol;hydrochloride)
• 1860738-05-1(CID 130513389)
• 2138311-90-5(3-Azetidinol, 3-[1-(aminomethyl)-2,2-dimethylcyclopropyl]-)
• 2751621-06-2(3-Cyclobutylazetidin-3-ol hydrochloride)
• 848392-21-2(3-cyclopropylazetidin-3-ol)
• 1820574-34-2((1R,6R)-3-azabicyclo[4.1.0]heptan-1-ol;hydrochloride)
• 2763908-79-6(3-(1-Methylcyclopropyl)azetidin-3-ol hydrochloride)